Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Semaglutide substantially reduced the risk of time to first composite outcome of HF events or CV death, as well as HF events and CV death alone, in a high-risk population with T2D and CKD. These effects were consistent regardless of history of HF. (A Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease [FLOW]; NCT03819153).
Authors
- George L. Bakris (ORCID: https://orcid.org/0000-0003-1183-1267)
- Søren Rasmussen
- Olav Wendelboe Nielsen (ORCID: https://orcid.org/0000-0003-3532-9431)
- Richard J. MacIsaac (ORCID: https://orcid.org/0000-0001-8058-6977)
- Samy Hadjadj (ORCID: https://orcid.org/0000-0001-7110-6994)
- Kenneth W. Mahaffey (ORCID: https://orcid.org/0000-0002-3791-2148)
- Johannes F.E. Mann (ORCID: https://orcid.org/0000-0002-3154-5332)
- Katherine R. Tuttle (ORCID: https://orcid.org/0000-0002-2235-0103)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Zdravko Asenov Kamenov (ORCID: https://orcid.org/0000-0002-4829-9449)
- Marco Bo Hansen (ORCID: https://orcid.org/0000-0002-5695-6728)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- Richard E. Pratley
- Vlado Perkovic
- Florian M.M. Baeres
- Thomas Idorn (ORCID: https://orcid.org/0009-0009-4896-5868)
Institutions
- University of Copenhagen (DK)
- American Heart Association (US)
- Steno Diabetes Centers (DK)
- The University of Melbourne (AU)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Novo Nordisk (Denmark) (DK)
- University of Washington (US)
- Inland Northwest Health Services (US)
- Medical University of Sofia (BG)
- UNSW Sydney (AU)
- University of Chicago (US)
- St Vincent's Hospital Melbourne (AU)
- Universitätsklinikum Erlangen (DE)
- Katholische Stiftungshochschule München (DE)
- Translational Research Institute for Metabolism and Diabetes (US)
- Stanford Medicine (US)
- Saint Luke's Hospital (US)
- Institut du Thorax (FR)
- Center for Clinical Research (United States) (US)
- University of Missouri–Kansas City (US)
- Nantes Université (FR)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.jacc.2024.08.004
- Citations
- 88
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 31.48
Funders
- European Commission
- Novo Nordisk